A Medical Device Daily

Altea Therapeutics (Atlanta) reported that it has entered into an agreement with Eli Lilly and Company (Indianapolis) and Amylin Pharmaceuticals (San Diego) to develop and commercialize a daily transdermal patch delivering sustained levels of exenatide using the Altea's PassPort Transdermal Delivery System in a deal valued at up to $46 million.

Altea, supported by Lilly and Amylin, recently completed an initial Phase 1 clinical study of the exenatide transdermal patch in people with Type 2 diabetes.

The exenatide transdermal patch is an investigational product designed to be applied once per day to provide sustained levels of exenatide for people with Type 2 diabetes. The potential benefits for patients from the exenatide transdermal patch include eliminating injections, which may increase therapy compliance.

Under terms of the agreement, Altea has granted Lilly and Amylin exclusive worldwide rights to develop and commercialize transdermal exenatide using PassPort Transdermal Delivery System. Lilly and Amylin will fund all product development, manufacturing, and commercialization activities for the product.

Altea will receive from Lilly and Amylin an upfront license payment and may receive clinical, regulatory and sales milestones of up to $46 million, and royalties on future product sales. As part of the agreement, an equity investment in Altea Therapeutics is included.

"This agreement continues the validation of the Altea Therapeutics transdermal patch technology for medicines that currently can be administered only by needle injection or infusion, including water-soluble proteins, carbohydrates, and small molecules," said Eric Tomlinson, PhD, DSc, president/CEO of Altea. "We believe the diabetes care experience of Lilly and Amylin, combined with the transdermal expertise of Altea Therapeutics creates an excellent partnership for the potential development of the world's first transdermal GLP-1 receptor agonist, transdermal exenatide."

"The agreement to develop a transdermal patch for exenatide is aimed at responding more broadly to the needs of the patients we serve by offering more treatment choices, such as the Altea Therapeutics non-injectable delivery option, for this important medicine," said Orville Kolterman, MD, senior vice president of research and development at Amylin.

In other agreements and contracts news:

iMedica (Dallas) has become a member benefit partner of Colorado Medical Society (CMS; Denver), the state's largest physician-based association representing more than 7,000 members. The relationship comes on the heels of the $19 billion in upcoming federal stimulus funds for health information technology, as well as a national commitment to provide everyone in the U.S. with an electronic health record (EHR) by 2014. The partnership also reinforces Colorado's priority to support the sharing of electronic health information across organizations.

As part of the terms of the agreement, CMS member physicians will receive preferred pricing on all iMedica products, as well as the opportunity to participate in live educational seminars designed to highlight the benefits, efficiencies and improved functionality that an EHR and practice management (PM) solution can bring to a medical practice.

Amerinet (St. Louis), a national healthcare group purchasing organization (GPO), reported the renewal of its agreement with Shriners Hospitals for Children (Tampa), which uses Amerinet's national portfolio of contracts and Total Spend Management business intelligence solutions to help manage its members' combined annual spend. The Shriners Hospitals for Children system represents several facilities throughout the U.S.

Specific benefits available to Shriners Hospitals for Children include contracts specially negotiated for system members, discounted pricing for all facility types, enhanced tier discounts for aggregated volume and customized educational solutions, through Amerinet's educational division, Inquisit.

Premier Purchasing Partners (San Diego) reported that new agreements for medical lasers and light based systems have been awarded to Lumenis (Santa Clara, California) and SSI Laser Engineering (Nashville, Tennessee).

Effective May 1, 2009, the agreements are available to acute care and continuum of care members of the Premier healthcare alliance.

Premier also reported new agreements for hand-carried ultrasound have been awarded to Sonosite (Bothel, Washington) and Terason Ultrasound (Burlington, Massachusetts). Effective April 1, 2009, the 36-month agreements are available to acute care and continuum of care members of the Premier healthcare alliance.

Analytix On Demand (Austin, Texas) and Pervasive Software (Irvine, California) are joining forces to deliver a business intelligence solution for the healthcare industry. Designed expressly for healthcare providers, large physician groups, hospitals, health plans and other healthcare organizations, the solution will provide a comprehensive, real-time view of business performance across clinical, financial and operational aspects of healthcare management.

No Comments